New large-scale DNA manufacturing facility in the UK
Touchlight, a UK-based manufacturer of synthetic DNA, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of the Morelands and Riverdale Buildings, a former Victorian water works on the River Thames. The facility will house 11 new state-of-the-art DNA production suites, bringing the total on site to 15 and more than tripling Touchlight’s London-based DNA manufacturing capacity.
Touchlight’s expansion is in direct response to the growing global demand for DNA, driven in particular by the advent of mRNA and DNA vaccines, alongside cell and gene therapies. Once operational in 2022, the facility will have the capacity to manufacture up to 1 kilogram of GMP DNA per month, enough for 1 billion mRNA vaccine doses.
Despite this significant production capacity, the benchtop scale of Touchlight’s proprietary dbDNA™ (“doggybone DNA” – a minimal, linear, covalently closed structure, that eliminates bacterial sequences) manufacturing technology enables a total facility footprint of just 7,500 sq ft, a fraction of the space required by conventional bioreactor-based plasmid DNA manufacture.
This landmark building project will support Touchlight’s continued growth, alongside the addition of up to 60 new employees, through the provision of additional essential laboratory and office space.
20/10/2021
New large-scale DNA manufacturing facility in the UK
New large-scale DNA manufacturing facility in the UK
Touchlight, a UK-based manufacturer of synthetic DNA, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of the Morelands and Riverdale Buildings, a former Victorian water works on the River Thames. The facility will house 11 new state-of-the-art DNA production suites, bringing the total on site to 15 and more than tripling Touchlight’s London-based DNA manufacturing capacity.
Touchlight’s expansion is in direct response to the growing global demand for DNA, driven in particular by the advent of mRNA and DNA vaccines, alongside cell and gene therapies. Once operational in 2022, the facility will have the capacity to manufacture up to 1 kilogram of GMP DNA per month, enough for 1 billion mRNA vaccine doses.
Despite this significant production capacity, the benchtop scale of Touchlight’s proprietary dbDNA™ (“doggybone DNA” – a minimal, linear, covalently closed structure, that eliminates bacterial sequences) manufacturing technology enables a total facility footprint of just 7,500 sq ft, a fraction of the space required by conventional bioreactor-based plasmid DNA manufacture.
This landmark building project will support Touchlight’s continued growth, alongside the addition of up to 60 new employees, through the provision of additional essential laboratory and office space.
20/10/2021
COMMENTS ARE OFF THIS POST